Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Revised NCCN guidelines emphasize the importance of cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. It recommends regular CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy. This approach aids in the ongoing monitoring of patients' conditions, ensuring comprehensive care. The updated guidelines reinforce the significance of CSF analysis in the clinical management of leptomeningeal metastases, underscoring the need for regular follow-ups to assess treatment efficacy and disease progression. These recommendations aim to optimize patient outcomes and enhance longitudinal monitoring of individuals with this condition.